Fate Therapeutics (FATE) Tops Q3 EPS by 2c

November 7, 2016 5:14 PM EST
Get Alerts FATE Hot Sheet
Trade FATE Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.27), $0.02 better than the analyst estimate of ($0.29).

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment